Are US Interchangeability Studies Worth It?

Biosimilar Switching Studies May Not Be Worth The Effort, Sponsors Say

 
• By Sue Sutter
  
conference
Biosimilars Review & Report's Stan Mehr, Samsung Bioepis' Sang-Jin Pak, Sandoz's Carol Lynch and Mylan's Chrys Kokino talk interchangeability at the AAM meeting. • Source: Sue Sutter

More from Biosimilars

More from Products